The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
Drug metabolism and pharmacokinetics, the blood-brain barrier, and central nervous system drug discovery
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The blood-brain barrier: Bottleneck in brain drug development
Pardridge, W. M. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.3 · Cited by 2,798
The blood–brain barrier: an overview
Ballabh, P., Braun, A., & Nedergaard, M. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.12.016 · Cited by 2,261
Ehringer, H., & Hornykiewicz, O. (1960) · Klinische Wochenschrift · doi:10.1007/bf01485901 · Cited by 1,867
Evans, D. A. (1989) · JAMA · doi:10.1001/jama.262.18.2551 · Cited by 1,626
Second-Generation (Atypical) Antipsychotics and Metabolic Effects: A Comprehensive Literature Review
Newcomer, J. W. (2005) · CNS Drugs · doi:10.2165/00023210-200519001-00001 · Cited by 1,340
Drug Metabolism and Variability among Patients in Drug Response
Wilkinson, G. R. (2005) · New England Journal of Medicine · doi:10.1056/nejmra032424 · Cited by 1,185
Blood-brain barrier active efflux transporters: ATP-binding cassette gene family
Löscher, W., & Potschka, H. (2005) · NeuroRX · doi:10.1602/neurorx.2.1.86 · Cited by 872
Permeability Studies on In Vitro Blood–Brain Barrier Models: Physiology, Pathology, and Pharmacology
Deli, M. A., Ábrahám, C. S., Kataoka, Y., & Niwa, M. (2005) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-004-1377-8 · Cited by 643
Doan, K. M. M., Humphreys, J. E., Webster, L. O., Wring, S. A., Shampine, L. J., Serabjit-Singh, C. J., Adkison, K. K., & Polli, J. W. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.039255 · Cited by 614
Evans, D. A., Funkenstein, H. H., Albert, M., Scherr, P. A., Cook, N. R., Chown, M. J., Hebert, L. E., Hennekens, C. H., & Taylor, J. O. (1989) · PubMed · Cited by 599
Cited by
Crossing the blood-brain barrier with nanoparticles
Zhou, Y., Peng, Z., Seven, E. S., & Leblanc, R. M. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.12.015 · Cited by 837
Antisense oligonucleotides: the next frontier for treatment of neurological disorders
Rinaldi, C., & Wood, M. J. A. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.148 · Cited by 788
Age-associated Physiological and Pathological Changes at the Blood-Brain Barrier: A Review
Erdő, F., Denes, L., & de Lange, E. (2017) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16679420 · Cited by 426
A Review on Central Nervous System Effects of Gastrodin
Liu, Y., Gao, J., Peng, M., Meng, H., Ma, H., Cai, P., Xu, Y., Zhao, Q., & Si, G. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00024 · Cited by 387
Liu, H., Wang, J., Zhou, W., Wang, Y., & Yang, L. (2013) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2013.02.004 · Cited by 326
Solid Lipid Nanoparticles (SLNs): An Advanced Drug Delivery System Targeting Brain through BBB
Satapathy, M. K., Yen, T.-L., Jan, J.-S., Tang, R.-D., Wang, J.-Y., Taliyan, R., & Yang, C.-H. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081183 · Cited by 318
Interpretation of Antibiotic Concentration Ratios Measured in Epithelial Lining Fluid
Kiem, S., & Schentag, J. J. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00133-06 · Cited by 289
Antisense oligonucleotides in therapy for neurodegenerative disorders
Evers, M. M., Toonen, L. J. A., & van Roon-Mom, W. M. C. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.03.008 · Cited by 286
Summerfield, S. G., Read, K., Begley, D. J., Obradovic, T., Hidalgo, I. J., Coggon, S., Lewis, A. V., Porter, R. A., & Jeffrey, P. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.121525 · Cited by 283
Nanoparticle transport across the blood brain barrier
Grabrucker, A. M., Ruozi, B., Belletti, D., Pederzoli, F., Forni, F., Vandelli, M. A., & Tosi, G. (2016) · Tissue Barriers · doi:10.1080/21688370.2016.1153568 · Cited by 217
“Estimates state that 1% of people over age 60 are affected by PD, the leading cause of the movement disorder called Parkinsonism.4 Clinical features of PD include tremor at rest, bradykinesia, rigidity and flexed posture.48 Pathologically, the key deficit in PD has been considered to be the loss of dopaminergic neuron…”
BackgroundNanoscale drug delivery systems and the blood–brain barrier
Khalin, I., Alyautdin, R., Ismail, N. M., Haron, M. H., & Kuznetsov, D. (2014) · International Journal of Nanomedicine · doi:10.2147/ijn.s52236 · Cited by 204
Connecting Vascular and Nervous System Development: Angiogenesis and the Blood-Brain Barrier
Tam, S. J., & Watts, R. J. (2010) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-060909-152829 · Cited by 197
Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases
Barchet, T. M., & Amiji, M. M. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240902758188 · Cited by 145
Privileged Electrophile Sensors: A Resource for Covalent Drug Development
Long, M. J. C., & Aye, Y. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.05.023 · Cited by 81
Therapeutic targeting of senescent cells in the CNS
Riessland, M., Ximerakis, M., Jarjour, A. A., Zhang, B., & Orr, M. E. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01033-z · Cited by 77
Ahmed, S. S. S. J., Husain, R. S. A., Kumar, S., & Ramakrishnan, V. (2016) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2016.07.041 · Cited by 32
Natural products as IL‐6 inhibitors for inflammatory diseases: Synthetic and SAR perspective
Harmalkar, D. S., Sivaraman, A., Nada, H., Lee, J., Kang, H., Choi, Y., & Lee, K. (2024) · Medicinal Research Reviews · doi:10.1002/med.22022 · Cited by 23
Metadata
- Authors
- Alavijeh, M. S., Chishty, M., Qaiser, M. Z., & Palmer, A. M.
- Venue
- NeuroRX
- Published
- 2005-10
- Volume
- 2
- Issue
- 4
- Pages
- 554-571
- ISSN
- 1545-5343 (ISSN-L)
- OpenAlex
- W2118857937
- Cited by
- 497
- References
- 89
- FWCI
- 2.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.